Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY.

Urology - 1 May 2004

Watanabe Jun, Nishiyama Hiroyuki, Okubo Kazutoshi, Takahashi Takeshi, Toda Yoshinobu, Habuchi Tomonori, Kakehi Yoshiyuki, Tada Mitsuhiro, Ogawa Osamu

Abstract excerpt

OBJECTIVES: To assess the clinical benefit of the methods of detection of p53 mutations in human urothelial carcinoma. METHODS: A total of 75 surgical specimens of urothelial carcinoma were analyzed using a yeast functional assay (FASAY) and immunohistochemistry (IHC), in combination with sequencing analysis. RESULTS: Of the 75 specimens, 24 (32.0%) were positive (mutant) by FASAY and 23 (30.7%) were positive by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Transitional Cell
Share to Chi-Square Distribution

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, p53

Share to Kidney Neoplasms

Share to Mutagenicity Tests

Share to Tumor Suppressor Protein p53

Share to Urinary Bladder Neoplasms

Share to Yeasts

Source

Identifiers

PMID: 15135005
DOI: 10.1016/j.urology.2003.11.031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY.PMID 15135005Read ↗

Assessment of p53 functional activity in tumor cells and histologically normal mucosa from patients with head and neck squamous cell carcinoma.Semantic proximity Read ↗

Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay.Semantic proximity Read ↗

Evaluation of methods to detect p53 mutations in ovarian cancer.Semantic proximity Read ↗

Screen p53 mutations in hepatocellular carcinoma by FASAY: a novel splicing mutation.Semantic proximity Read ↗

p53 status in breast carcinomas revealed by FASAY correlates well with p53 protein accumulation determined by immunohistochemistry.Semantic proximity Read ↗

Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.Semantic proximity Read ↗

Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.Semantic proximity Read ↗

Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124.Semantic proximity Read ↗

Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response.Semantic proximity Read ↗

Correlations of breast carcinoma biomarkers and p53 tested by FASAY and immunohistochemistry.Semantic proximity Read ↗

p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry.Semantic proximity Read ↗

Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.